Korean J Gynecol Oncol.  2006 Dec;17(4):286-293.

A role of Cyclosporine A that suppresses multi-drug resistance (MDR) in the secondary chemotherapy drug resistant cell line of ovarian cancer

• An CS
• Kim SY
• Park CM

Abstract

OBJECTIVE
Resistant, recurrent ovarian cancer patients who had first chemotherapy with Cisplatin have showed low reactivity and high recurrence in the secondary chemotherapy. Therefore, multi-drug resistance (MDR) to chemotherapy is a major obstacle in attempts to improve the clinical outcome of ovarian cancer patients. The aim of our study is to analyze the sensitivity of some chemotherapy drugs when we co-use Cyclosporine A (CsA), which suppresses MDR, in the secondary drug resistant cell line.
METHODS
After establishing the secondary drug resistant cell line, drug sensitivity was measured by MTT assay. MDR gene and protein were analyzed by RT-PCR and western blotting assay.
RESULTS
MDR gene (MDR1) and protein (P-gp) were overexpressed in the secondary drug resistant cell line. When we measured the sensitivity of some chemotherapy drug after using the amounts of CsA that can suppress MDR1/P-gp, the sensitivity of Paclitaxel was highest.
CONCLUSION
CsA has a role that makes the sensitivity of chemotherapy drug higher in the secondary drug resistant cell line by suppression of multi-drug resistance. Therefore, we could expect that the proper use of MDR suppresser like CsA with secondary chemotherapy drug would help to cure resistant, recurrent ovarian cancer patients.

Keyword

Ovarian cancer; Multi-drug resistance; MDR1/P-gp; Cyclosporine A

MeSH Terms

Blotting, Western
Cell Line*
Cisplatin
Cyclosporine*
Drug Resistance, Multiple*
Drug Therapy*
Genes, MDR
Humans
Ovarian Neoplasms*
Paclitaxel
Recurrence
Cisplatin
Cyclosporine
Paclitaxel